- UroToday Home
- Urologic Oncology
The Latest Bladder Cancer Research
Recent Abstracts
-
Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.Bladder CancerJune 25, 2026
-
A Pilot Study of Ex-vivo High Frequency Ultrasound and Core Needle Biopsy to Improve Clinical Tumor Staging of Cancer of the Bladder.Bladder CancerJune 25, 2026
-
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline UpdateBladder CancerJune 24, 2026
-
CRISPR/Cas9-mediated miR-21 editing in high-grade urothelial carcinoma cells and its biological effects.Bladder CancerJune 24, 2026
-
Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.Bladder CancerJune 24, 2026
-
Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients.Bladder CancerJune 23, 2026
-
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.Bladder CancerJune 23, 2026
-
Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.Bladder CancerJune 23, 2026
-
Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.Bladder CancerJune 22, 2026
-
Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.Bladder CancerJune 22, 2026
Beyond the Abstracts
-
Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter - Beyond the AbstractBladder CancerJune 17, 2026
-
Impact of Asymptomatic Bacteriuria on the Outcomes and Tolerability of Bacillus Calmette-Guérin Immunotherapy - Beyond the AbstractBladder CancerJune 16, 2026
-
HER2 and Urothelial Carcinoma: Current Understanding and Future Directions - Beyond the AbstractBladder CancerJune 16, 2026
-
Detection of Bladder Cancer in Patients with Microscopic Hematuria Using Oncuria-Detect: Results of a Prospective, Multicenter International Study - Beyond the AbstractBladder CancerMay 26, 2026
-
Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design - Beyond the AbstractBladder CancerMay 22, 2026
-
Impact of Pelvic Lymph Node Dissection on Oncological Outcomes in Patients with Clinically Staged Non-Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Systematic Review - Beyond the AbstractBladder CancerMay 22, 2026
-
Population-Based Outcomes of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer in Older Adults - Beyond the AbstractBladder CancerMay 21, 2026
-
Advances and Challenges of PET Imaging in Bladder Cancer-an Update and Future Trends - Beyond the AbstractBladder CancerMay 20, 2026
-
Real-World Effectiveness of Avelumab, Pembrolizumab, and Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma with Squamous Differentiation (ARON-2EV) - Beyond the AbstractBladder CancerMay 14, 2026
-
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists - Beyond the AbstractBladder CancerMay 7, 2026